Atle Fund Management AB Purchases 5,004 Shares of Gilead Sciences, Inc. $GILD

Core Viewpoint - Atle Fund Management AB increased its holdings in Gilead Sciences by 6.8% in Q3, indicating growing institutional interest in the biopharmaceutical company [2] Institutional Holdings - Norges Bank acquired a new stake in Gilead valued at approximately $2.15 billion in Q2 - Ameriprise Financial increased its stake by 397.6% in Q2, now owning 6,748,403 shares valued at $748.15 million after purchasing an additional 5,392,191 shares - Invesco Ltd. raised its position by 33.5% in Q2, now holding 13,521,228 shares worth $1.50 billion after buying 3,394,330 shares - Assenagon Asset Management increased its holdings by 164.4% in Q3, now owning 3,489,062 shares valued at $387.29 million after acquiring 2,169,266 shares - Vanguard Group lifted its stake by 1.6% in Q2, now owning 119,364,226 shares worth $13.23 billion after acquiring 1,893,401 shares - Institutional investors and hedge funds currently own 83.67% of Gilead's stock [3] Stock Performance - Gilead Sciences shares opened at $141.95, with a market cap of $176.11 billion - The stock has a price-to-earnings ratio of 22.01, a PEG ratio of 0.73, and a beta of 0.33 - The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45, and a quick ratio of 1.31 - The one-year low for the stock is $93.37, and the one-year high is $142.20 [4] Earnings Results - Gilead reported an EPS of $2.47 for the latest quarter, exceeding the consensus estimate of $2.16 by $0.31 - The company achieved a net margin of 27.88% and a return on equity of 51.86% - Quarterly revenue was $7.77 billion, surpassing the consensus estimate of $7.42 billion, and up 3.0% year-over-year - Analysts expect Gilead to post an EPS of 7.95 for the current year [5] Analyst Ratings - Leerink Partners raised their price target from $114.00 to $146.00, rating the stock as "outperform" - Rothschild & Co Redburn increased their target from $153.00 to $159.00 with a "buy" rating - Sanford C. Bernstein set a price objective of $135.00 with an "outperform" rating - Citigroup raised their target from $140.00 to $156.00 with a "buy" rating - HSBC lifted their target from $110.00 to $133.00 with a "hold" rating - The stock has a consensus rating of "Moderate Buy" with an average target price of $136.73 [6] Insider Activity - Director Kelly A. Kramer sold 2,805 shares at an average price of $127.10, totaling $356,515.50, reducing ownership by 67.69% - CFO Andrew D. Dickinson sold 3,000 shares at an average price of $124.31, totaling $372,930.00, a 1.95% decrease in ownership - Over the last 90 days, insiders sold 257,397 shares worth $33.39 million, with insiders owning 0.27% of the company's stock [8] Company Overview - Gilead Sciences, founded in 1987 and headquartered in Foster City, California, focuses on developing medicines for high unmet medical needs - The company is known for its antiviral therapies and has expanded into oncology, cell therapy, and inflammatory diseases [9][10]